CA2308584A1 - Apport cible de gene dans un liposome vecteur - Google Patents
Apport cible de gene dans un liposome vecteur Download PDFInfo
- Publication number
- CA2308584A1 CA2308584A1 CA002308584A CA2308584A CA2308584A1 CA 2308584 A1 CA2308584 A1 CA 2308584A1 CA 002308584 A CA002308584 A CA 002308584A CA 2308584 A CA2308584 A CA 2308584A CA 2308584 A1 CA2308584 A1 CA 2308584A1
- Authority
- CA
- Canada
- Prior art keywords
- liposome
- nucleic acid
- vector
- complex
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 title claims abstract 48
- 238000001476 gene delivery Methods 0.000 title 1
- 239000013598 vector Substances 0.000 claims abstract 54
- 239000003446 ligand Substances 0.000 claims abstract 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract 12
- 241000700605 Viruses Species 0.000 claims abstract 11
- 102000004338 Transferrin Human genes 0.000 claims abstract 10
- 108090000901 Transferrin Proteins 0.000 claims abstract 10
- 229940014144 folate Drugs 0.000 claims abstract 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract 10
- 235000019152 folic acid Nutrition 0.000 claims abstract 10
- 239000011724 folic acid Substances 0.000 claims abstract 10
- 239000012581 transferrin Substances 0.000 claims abstract 10
- 201000011510 cancer Diseases 0.000 claims abstract 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract 6
- 238000012385 systemic delivery Methods 0.000 claims abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 3
- 238000001727 in vivo Methods 0.000 claims abstract 3
- 238000001959 radiotherapy Methods 0.000 claims abstract 3
- 108020004707 nucleic acids Proteins 0.000 claims 44
- 102000039446 nucleic acids Human genes 0.000 claims 44
- 150000007523 nucleic acids Chemical class 0.000 claims 44
- 238000000034 method Methods 0.000 claims 26
- 125000002091 cationic group Chemical group 0.000 claims 8
- 150000002632 lipids Chemical class 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- -1 cationic lipid Chemical class 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 230000001093 anti-cancer Effects 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 abstract 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 230000035572 chemosensitivity Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000012637 gene transfection Methods 0.000 abstract 1
- 230000009036 growth inhibition Effects 0.000 abstract 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 108700025694 p53 Genes Proteins 0.000 abstract 1
- 208000023958 prostate neoplasm Diseases 0.000 abstract 1
- 208000013274 squamous cell breast carcinoma Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
- 238000012384 transportation and delivery Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
On décrit des complexes (vecteurs) ciblés constitués d'un ligand, d'un liposome et d'une molécule thérapeutique qui sont utilisés pour apporter de manière systémique la molécule thérapeutique à divers types de cellules cibles, y compris à des cellules cancéreuses telles que celles de l'épithélioma spinocellulaire de la tête et du cou, et des tumeurs du sein et de la prostate. Les ligands préférés, le folate et la transferrine, ciblent le complexe de liposome et facilitent la transfection du gène transitoire. L'apport systémique de complexes contenant de l'ADN codant le gène p53 du type sauvage à des hétérogreffes établies de souris a manifestement sensibilisé les tumeurs à la radiothérapie et à la chimiothérapie. La combinaison de la thérapie du gène p53 systémique et de la radiothérapie ou de la chimiothérapie classique a eu pour effet la régression totale des tumeurs et l'inhibition à long terme de la récurrence. Ce système d'apport à spécificité cellulaire a également été utilisé in vivo pour apporter avec succès, par administration intraveineuse, de petites molécules d'ADN (oligonucléotides) qui ont induit une chimiosensibilité et l'inhibition de la croissance des hétérogreffes. D'autres molécules thérapeutiques, y compris des virus non transformés, peuvent être encapsulées dans un complexe et ciblées selon l'invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2739604A CA2739604C (fr) | 1997-11-19 | 1998-11-19 | Apport cible de gene dans un liposome vecteur |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6618897P | 1997-11-19 | 1997-11-19 | |
| US60/066,188 | 1997-11-19 | ||
| US8317598P | 1998-04-27 | 1998-04-27 | |
| US60/083,175 | 1998-04-27 | ||
| PCT/US1998/024657 WO1999025320A1 (fr) | 1997-11-19 | 1998-11-19 | Apport cible de gene dans un liposome vecteur |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2739604A Division CA2739604C (fr) | 1997-11-19 | 1998-11-19 | Apport cible de gene dans un liposome vecteur |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2308584A1 true CA2308584A1 (fr) | 1999-05-27 |
| CA2308584C CA2308584C (fr) | 2011-07-19 |
Family
ID=26746455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2308584A Expired - Fee Related CA2308584C (fr) | 1997-11-19 | 1998-11-19 | Apport cible de gene dans un liposome vecteur |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1166775B1 (fr) |
| JP (2) | JP2001522871A (fr) |
| CN (3) | CN1616665B (fr) |
| AT (2) | ATE295722T1 (fr) |
| AU (1) | AU759164C (fr) |
| CA (1) | CA2308584C (fr) |
| DE (2) | DE69841536D1 (fr) |
| DK (1) | DK1166775T3 (fr) |
| ES (1) | ES2339421T3 (fr) |
| HK (1) | HK1045641B (fr) |
| PT (1) | PT1166775E (fr) |
| WO (1) | WO1999025320A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1811036E (pt) | 1999-02-22 | 2011-07-11 | Univ Georgetown | Imunolipossomas dirigidos por fragmento de anticorpo para distribuição sistémica de genes |
| US9034330B2 (en) | 1999-02-22 | 2015-05-19 | Georgetown University | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
| US8617514B2 (en) | 1999-02-22 | 2013-12-31 | Georgetown University | Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
| US7780882B2 (en) | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
| US9034329B2 (en) | 1999-02-22 | 2015-05-19 | Georgetown University | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
| US7109165B2 (en) * | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| WO2004066908A2 (fr) * | 2003-01-17 | 2004-08-12 | Sanofi Pasteur | Composition comprenant lipides cationiques et un polynucleotide ou un polpeptide et methode pour leur delivrance ciblee |
| CA2513769A1 (fr) * | 2003-01-28 | 2004-08-12 | Georgetown University | Procede pour l'evaluation de l'efficacite de certains traitements du cancer |
| CN1327899C (zh) * | 2003-05-10 | 2007-07-25 | 彭朝晖 | 腺病毒载体与p53基因的基因重组体的应用 |
| AU2004251680B2 (en) * | 2003-06-04 | 2010-02-18 | Georgetown University | Method for improving stability and shelf-life of liposome complexes |
| US8627821B2 (en) | 2005-01-10 | 2014-01-14 | Pulmatrix, Inc. | Method and device for decreasing contamination |
| JP5102630B2 (ja) * | 2005-11-24 | 2012-12-19 | ジェノミディア株式会社 | 改変パラミクソウイルスおよびその作製方法 |
| CN102133404B (zh) * | 2011-03-23 | 2013-01-16 | 成都诺恩生物科技有限公司 | 一种肿瘤靶向治疗药物载体、其制备方法及其应用 |
| MX2014007664A (es) | 2011-12-22 | 2015-05-11 | Nuvo Res Gmbh | Composiciones liposomicas de clorito o clorato. |
| CN103655475B (zh) | 2012-09-19 | 2020-04-28 | 乔治敦大学 | 靶向的脂质体 |
| US20140120157A1 (en) | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| CA2901616A1 (fr) | 2013-03-14 | 2014-10-02 | Georgetown University | Traitement apres l'exposition a un agent neurotoxique |
| US10709761B2 (en) | 2015-10-08 | 2020-07-14 | University Of Utah Research Foundation | Methods and compositions for preventing or treating cancer |
| EP3538546B1 (fr) | 2016-11-14 | 2025-01-08 | Novartis AG | Compositions, procédés et utilisations thérapeutiques relatifs à la protéine fusogène minion |
| WO2020077039A1 (fr) | 2018-10-12 | 2020-04-16 | Synergene Therapeutics, Inc. | Procédés de réduction des effets secondaires de l'immunothérapie |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635380A (en) * | 1994-01-18 | 1997-06-03 | Vanderbilt University | Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids |
| US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
| WO1996008263A1 (fr) * | 1994-09-13 | 1996-03-21 | Theratech, Inc. | Administration intracellulaire d'agents chimiques a un type specifique de cellules |
| US20020051767A1 (en) * | 1995-09-13 | 2002-05-02 | Yawen L. Chiang | Cancer treatment |
| JPH09110722A (ja) * | 1995-10-20 | 1997-04-28 | Toray Ind Inc | 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法 |
| ATE333892T1 (de) * | 1996-02-09 | 2006-08-15 | Pi-Wan Cheng | Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen |
| JP3956402B2 (ja) * | 1996-03-04 | 2007-08-08 | 日本油脂株式会社 | アンホテリシンｂ運搬体 |
-
1998
- 1998-11-19 DK DK01123562.9T patent/DK1166775T3/da active
- 1998-11-19 AU AU14642/99A patent/AU759164C/en not_active Ceased
- 1998-11-19 EP EP01123562A patent/EP1166775B1/fr not_active Expired - Lifetime
- 1998-11-19 DE DE69841536T patent/DE69841536D1/de not_active Expired - Lifetime
- 1998-11-19 JP JP2000520754A patent/JP2001522871A/ja active Pending
- 1998-11-19 DE DE69830249T patent/DE69830249T2/de not_active Expired - Lifetime
- 1998-11-19 PT PT01123562T patent/PT1166775E/pt unknown
- 1998-11-19 CA CA2308584A patent/CA2308584C/fr not_active Expired - Fee Related
- 1998-11-19 CN CN2004100824737A patent/CN1616665B/zh not_active Expired - Fee Related
- 1998-11-19 CN CNB988131773A patent/CN1191094C/zh not_active Expired - Fee Related
- 1998-11-19 ES ES01123562T patent/ES2339421T3/es not_active Expired - Lifetime
- 1998-11-19 CN CNA2006101003252A patent/CN1904055A/zh active Pending
- 1998-11-19 EP EP98958643A patent/EP1032369B1/fr not_active Expired - Lifetime
- 1998-11-19 AT AT98958643T patent/ATE295722T1/de not_active IP Right Cessation
- 1998-11-19 WO PCT/US1998/024657 patent/WO1999025320A1/fr not_active Ceased
- 1998-11-19 AT AT01123562T patent/ATE459340T1/de not_active IP Right Cessation
-
2002
- 2002-07-02 HK HK02104922.3A patent/HK1045641B/en not_active IP Right Cessation
-
2010
- 2010-08-19 JP JP2010184261A patent/JP2010263920A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT1166775E (pt) | 2010-04-16 |
| HK1045641B (en) | 2010-10-29 |
| EP1032369A1 (fr) | 2000-09-06 |
| AU759164B2 (en) | 2003-04-10 |
| DE69841536D1 (de) | 2010-04-15 |
| DE69830249T2 (de) | 2006-05-04 |
| CN1616665A (zh) | 2005-05-18 |
| CN1286630A (zh) | 2001-03-07 |
| CN1191094C (zh) | 2005-03-02 |
| EP1032369B1 (fr) | 2005-05-18 |
| EP1166775A3 (fr) | 2003-06-25 |
| DK1166775T3 (da) | 2010-05-03 |
| HK1078608A1 (en) | 2006-03-17 |
| WO1999025320A1 (fr) | 1999-05-27 |
| AU1464299A (en) | 1999-06-07 |
| EP1166775B1 (fr) | 2010-03-03 |
| AU759164C (en) | 2007-03-29 |
| ATE295722T1 (de) | 2005-06-15 |
| CA2308584C (fr) | 2011-07-19 |
| HK1045641A1 (en) | 2002-12-06 |
| JP2001522871A (ja) | 2001-11-20 |
| CN1616665B (zh) | 2010-10-06 |
| CN1904055A (zh) | 2007-01-31 |
| DE69830249D1 (de) | 2005-06-23 |
| HK1035490A1 (en) | 2001-11-30 |
| EP1166775A2 (fr) | 2002-01-02 |
| JP2010263920A (ja) | 2010-11-25 |
| ATE459340T1 (de) | 2010-03-15 |
| ES2339421T3 (es) | 2010-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2308584A1 (fr) | Apport cible de gene dans un liposome vecteur | |
| Hattori et al. | Folate-linked lipid-based nanoparticle for targeted gene delivery | |
| Gao et al. | Supramolecular macrophage‐liposome marriage for cell‐hitchhiking delivery and immunotherapy of acute pneumonia and melanoma | |
| Santana-Armas et al. | Strategies for cancer gene-delivery improvement by non-viral vectors | |
| Zhao et al. | Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor | |
| Tam et al. | Stabilized plasmid-lipid particles for systemic gene therapy | |
| US6749863B1 (en) | Targeted liposome gene delivery | |
| Monck et al. | Stabilized plasmid–lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection | |
| US6372250B1 (en) | Non-invasive gene targeting to the brain | |
| Ko et al. | Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK) 2 and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy | |
| Vasileva et al. | Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics | |
| EP1033972B1 (fr) | Systeme d'administration d'un medicament avec ciblage en deux temps | |
| Chu et al. | Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders | |
| US7262173B2 (en) | Chemosensitizing with liposomes containing oligonucleotides | |
| Xulº et al. | Systemic p53 gene therapy in combination with radiation results in human tumor regression | |
| Wang et al. | RETRACTED ARTICLE: Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment: Wang and Zhang | |
| JP2001522871A5 (fr) | ||
| Hegde et al. | Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects | |
| WO2023230711A1 (fr) | Nanoparticule lipidique pour l'administration d'arn | |
| Idani et al. | Intra‐tumoral injection of doxorubicin (adriamycin) encapsulated in liposome inhibits tumor growth, prolongs survival time and is not associated with local or systemic side effects | |
| Yang et al. | Photoimmunotherapy biomimetic nanoplatform for lung cancer and brain metastasis | |
| Lu et al. | Enhancement of p53 gene transfer efficiency in hepatic tumor mediated by transferrin receptor through trans-arterial delivery | |
| JP2010213726A (ja) | 全身性ウイルス／リガンド遺伝子送達システムおよび遺伝子治療 | |
| CA2739604C (fr) | Apport cible de gene dans un liposome vecteur | |
| Hattori | Cancer gene delivery with folate receptor targeting lipid-based nanoparticle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20181119 |
|
| MKLA | Lapsed |
Effective date: 20181119 |